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Abstract
Background In Europe, changes to pharmacovigilance
legislation, which include additional monitoring of
medicines, aim to optimise adverse drug reaction (ADR)
reporting systems. The legislation also makes provisions
related to the traceability of biological medicines.
Objective The objective of this study was to assess
(i) knowledge and general experience of ADR reporting, (ii)
knowledge, behaviours, and attitudes related to the pharma-
covigilance of biologicals, and (iii) awareness of additional
monitoringamonghealthcareprofessionals (HCPs) in Ireland.
Methods Hospital doctors (n = 88), general practitioners
(GPs) (n = 197), nurses (n = 104) and pharmacists
(n = 309) completed an online questionnaire.
Results There were differences in mean knowledge scores
relating to ADR reporting and the pharmacovigilance of
biologicals among the HCP groups. The majority of HCPs
who use biological medicines in their practice generally
record biologicals by brand name but practice behaviours
relating to batch number recording differed between some
professions. HCPs consider batch number recording to be
valuable but also regard it as being more difficult than
brand name recording. Most respondents were aware of the
concept of additional monitoring but awareness rates dif-
fered between some groups. Among those who knew about
additional monitoring, there was higher awareness of the
inverted black triangle symbol among pharmacists
([86.4%) compared with hospital doctors (35.1%), GPs
(35.6%), and nurses (14.9%). Hospital pharmacists had
more experience and knowledge of ADR reporting than
other practising HCPs.
Conclusion This study highlights the important role hos-
pital pharmacists play in post-marketing surveillance.
There is a need to increase pharmacovigilance awareness
of biological medicines and improve systems to support
their batch traceability.
Key Points
There were differences in experience and knowledge
of ADR reporting as well as confidence in the ability
to report ADRs among hospital doctors, general
practitioners, nurses, and pharmacists
Healthcare-professional awareness of additional
monitoring was high. However, pharmacists were
significantly more aware of the inclusion of the
inverted black triangle symbol . on the product
information of such medicines than hospital doctors,
general practitioners, and nurses
Overall, healthcare professionals were more familiar
with the term biological medicine than biosimilar
medicine. Biological medicines are typically
recorded by brand name but batch numbers are
recorded to a lesser extent. This may negatively
impact the traceability of biologicals to batch level in
ADR reporting databases
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1 Introduction
Pharmacovigilance refers to the ongoing assessment of a
medicine’s safety throughout its lifecycle [1]. Adverse drug
reaction (ADR) reporting is a key source of information for
safety signal detection activities and is useful in the iden-
tification of rare adverse events [2]. However, it is esti-
mated that only 6% of ADRs are reported [3]. Factors that
may contribute to underreporting among healthcare pro-
fessionals (HCPs) include knowledge, negative attitudes,
lack of time and motivation [4]. Lack of standardised
reporting processes and gaps in healthcare information
systems also contribute to underreporting [5]. New phar-
macovigilance legislation, which came into effect in Eur-
ope in July 2012, resulted in specific changes related to
ADR reporting including provision for direct patient
reporting of ADRs and additional monitoring of medicines
[6]. Additional monitoring aims to encourage ADR
reporting, thereby allowing additional safety data to be
gathered for medicines containing new active substances or
medicines with emerging safety issues. The additional
monitoring status of a medicine is indicated by the pres-
ence of an inverted black triangle symbol ., accompanied
by an explanatory statement encouraging the reporting of
ADRs, on the Summary of Product Characteristics (SmPC)
and the Package Leaflet (PL) [7]. The revised pharma-
covigilance legislation also made provisions related to the
traceability of biological medicines. As such, brand name
and batch numbers should be included in ADR reports for
biological medicines [8].
Biological medicines pose specific challenges for phar-
macovigilance. A recent guideline published by the Euro-
pean Medicines Agency (EMA) highlights four key
considerations for the pharmacovigilance of biologicals;
namely immunogenicity, manufacturing variability, sta-
bility/cold chain requirements and product traceability [9].
Biological medicines are inherently variable and although
different batches of the same biological medicine are not
identical, the quality of each batch is tightly controlled to
ensure the safety and efficacy of the medicine [10]. How-
ever, necessary manufacturing process changes [10] can
impact quality attributes of the biological and this can
occur unbeknownst to healthcare professionals and patients
[11]. In rare instances, these changes can have unforeseen
effects on the immunogenicity of a product [12]. Biological
medicines including biosimilars are becoming increasingly
available [13]. Biosimilars are distinct from the generics of
chemical medicines as, owing to the complexities of bio-
logical substances and their manufacturing processes,
biosimilars are not completely identical to the original
medicine on which they are based (reference medicine).
Similarity to the reference medicine is demonstrated
through a rigorous comparability exercise conducted at the
quality, pre-clinical and clinical levels [14]. All newly
approved biological medicines, including biosimilars, are
subject to additional monitoring for a period of 5 years
after approval.
The traceability of biologicals is essential so that the
impact of suspected ADRs can be properly evaluated to
both product and batch level. Contrary to naming approa-
ches taken in the United States [15], a biosimilar in Europe
has the same international non-proprietary name (INN) as
its reference medicine, even though it is not its generic
equivalent. Therefore, inclusion of the brand name in ADR
reports allows differentiation to be made between products.
Product-specific pharmacovigilance also allows changes in
product quality or characteristics that may result in clini-
cally meaningful differences arising between products with
the same INN [9, 16] to be captured. Traceability to batch
level is necessary to signal batch-specific issues or flag
adverse reactions attributable to manufacturing process
changes [17]. Consequently, HCPs are advised to system-
atically record and report detailed exposure information for
all biological medicines [18].
In most cases, biologicals are prescribed in specialised
hospital settings; however, patients receiving these
medicines are usually cared for by multidisciplinary teams
composed of hospital doctors, nurses, general practitioners
(GPs) and pharmacists. Biological medicines have specific
pharmacovigilance considerations and all newly approved
biologicals are subject to additional monitoring. An
appreciation of these considerations by HCPs helps to
ensure the safe and effective use of biological medicines.
Several studies on knowledge of ADR reporting among
HCPs have been conducted previously [19–23] and the
findings suggest knowledge of, as well as communication
and training on ADR reporting could be improved. How-
ever, there appear to be no studies that address HCP
knowledge of the pharmacovigilance of biological medi-
cines. It is also not known if HCPs in Europe are aware of
additional monitoring. A survey of a diverse group of
HCPs in Ireland was conducted in order to assess and
compare (i) knowledge and general experience of ADR
reporting, (ii) knowledge, behaviours and attitudes related
to the pharmacovigilance of biologicals and (iii) awareness
of additional monitoring.
2 Methods
2.1 Questionnaire Design
A questionnaire was developed based on previously pub-
lished studies [13, 19, 24–27]. The questionnaire wording
was agreed by a panel of experts with backgrounds in
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regulation, clinical pharmacy, pharmacovigilance, acade-
mia and regulatory affairs. The face validity of the ques-
tionnaire was tested in a pilot study using a convenience
sample of 18 HCPs. Minor modifications were made to
some of the questions after the pilot study to improve
clarity. On the basis of the pilot study it was estimated that
the questionnaire would take 5–10 min to complete.
The questionnaire consisted of an information letter with
informed consent statement and a total of 26 questions,
including questions consisting of multiple choice state-
ments. Not all questions had to be answered as respondents
were directed towards questions that were relevant to them
using an in-built ‘survey-monkey logic’ tool. Two sets of
closed questions were used to measure knowledge. Each
set of closed questions contained eight statements and
respondents were asked to respond ‘yes’, ‘no’ or ‘don’t
know’ to each statement. The first set related to ADR
reporting. Seven of the eight statements had been used in
previous surveys of medical students, pharmacy students
and pharmacists [19, 24, 25]. The second set of closed
questions contained eight statements relating to specific
pharmacovigilance considerations for biological medi-
cines. A brief explanation of the term biological medicine
was provided. The questionnaire is provided in the elec-
tronic supplementary material (ESM).
Two dichotomous closed questions were used to estab-
lish respondent’s knowledge of the concept of ‘additional
monitoring’ (a brief explanation of this term was provided)
and the presence of the inverted black triangle . on pro-
duct information. A 5-point Likert scale was used to
establish awareness and behaviours related to additional
monitoring among HCPs who had knowledge of this con-
cept. Familiarity with the terms ‘biological medicine’ and
‘biosimilar medicine’ was established using two multiple-
choice questions. Respondents who prescribed, dispensed
or administered biological medicines were asked questions
related to traceability of biologicals in their practice.
Attitudes related to the value and difficulty of brand name
and batch number recording were assessed on two different
scales. The first scale was anchored by ‘Worthless (1) to
Valuable (7)’ and the second scale by ‘Easy (1) to Difficult
(7)’.
2.2 Questionnaire Distribution
The questionnaire was made available to HCPs online
(hosted at http://www.surveymonkey.com) from May to
July 2017. The HCP groups were hospital doctors (prac-
tising at consultant [specialist] or non-consultant level),
GPs (doctors working in primary care), nurses and phar-
macists. Hospital doctors and GPs were invited to complete
the questionnaire in emails circulated to members by the
Royal College of Physicians in Ireland and the Irish
College of GPs, respectively. The Office of Nursing and
Midwifery Services in the Irish Health Service Executive
requested senior nurses to distribute the survey link to their
nursing staff. Finally, the Pharmaceutical Society of Ire-
land provided details of members’ email addresses to one
member of the research team (JOC). One reminder email
was sent to nurses and GPs. Due to project time constraints,
hospital doctors and pharmacists did not receive any
reminders. No honorarium was provided to respondents.
2.3 Statistical Analysis
All data were analysed using IBM SPSS Statistics Version
23. Each respondent’s knowledge level relating to (i) ADR
reporting and (ii) the pharmacovigilance of biologicals was
calculated by summing all correct items and dividing by
the total number of items. Comparison between categorical
variables was performed using the Chi square test for
independence. Independent t tests or one-way Analysis of
Variance (ANOVA) was used to compare mean knowledge
scores with baseline characteristics. The Mann–Whitney
U test or the Kruskal–Wallis test were used to confirm
findings in cases where not all assumptions of the para-
metric tests were met. A 5% significance level applies
throughout all hypothesis testing. A Bonferroni correction
was applied when multiple group comparisons were made.
In cases where 15 comparisons were made, the alpha level
was adjusted to 0.003, where five comparisons were made,
the alpha level was 0.01.
2.4 Analysis of Adverse Drug Reaction (ADR)
Database
Information on the sources of suspected new ADR reports
was obtained from annual reports published by the Health
Products Regulatory Authority (HPRA, formerly Irish
Medicines Board) for a 5-year period (2012–2016).
Reports are published on the HPRA website [28]. ADR
reports for biological medicines containing epoetins, fil-
grastims and infliximab were extracted from the HPRA
ADR database. The reports covered a 5-year period
(2013–2017). These substances were chosen as both ref-
erence and biosimilar products were available on the Irish
marketplace. Reports were reviewed for inclusion of brand
name and batch number details.
2.5 Ethical Considerations
The research study was approved by the Social Research
Ethics Committee (SREC) in University College Cork,
Ireland (Log 2017-039).
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3 Results
A total of 821 responses were received. The email invite
was sent to a total of 2360 hospital doctors (97 responses
received), 2900 GPs (238 responses received) and 5837
pharmacists (349 responses received). This corresponded
to response rates of 4, 8 and 6% for hospital doctors, GPs
and pharmacists respectively. Responses were also
received from 121 nurses. Response rates could not be
calculated for nurses as it could not be determined how
many senior nurses forwarded the link to their nursing
staff. A total of 16 respondents categorised themselves as
‘other’. There were 708 complete responses. Of this
number, eight did not meet the inclusion criteria (i.e.
hospital doctor, GP, nurse or pharmacist) and were
excluded from the final analysis. Two pharmacists that
did not provide details of their practice area were also
excluded. Consequently, responses from 698 HCPs were
analysed.
3.1 Demographics
Respondents were grouped according to profession.
Pharmacists were further categorised according to their
practice setting. Those pharmacists who did not work in
community and hospital pharmacies were classified as
‘other’ pharmacists. This group generally represented
pharmacists working in industry, academia or regulation,
and as such this group were not considered to be prac-
tising HCPs. A total of 88 hospital doctors completed the
questionnaire. The majority of hospital doctors were
consultants (specialists) (67%, n = 59) and 33% (n = 29)
were non-consultant hospital doctors. The hospital doctors
came from a wide variety of specialities (see Table S1,
ESM). Almost half (47%, n = 42) worked in specialities
where biological medicines are commonly used. Only one
hospital doctor did not prescribe medicines to their
patients. Nurses also came from a variety of backgrounds
(see Table S2, ESM). Nurses had the most experience,
with over 74% of nurses surveyed having 20 or more
years’ professional experience. The ‘other’ pharmacists
were the least experienced, with 44% of this group having
\ 10 years of experience. Respondents were also asked if
biological medicines were prescribed, dispensed or
administered in their practice. Group demographics are
summarised in Table 1.
The majority of respondents knew that ADRs could be
reported directly to the HPRA. Analysis by profession
found that 60.6% (n = 63) of nurses, 82.2% (n = 162) of
GPs, 86.4% (n = 76) of hospital doctors, 93.5% (n = 158)
of community pharmacists, 96.2% (n = 51) of ‘other’
pharmacists and 98.9% (n = 86) of hospital pharmacists
knew this. Nurses had lower awareness of this fact than
each of the other groups (p\0.001 in all cases, Chi square
test for independence). GPs were also less aware of this
than community or hospital pharmacists (p = 0.002 and
p\0.001, respectively, Chi square test for independence).
3.2 Sources of ADR Reports
The HPRA received an average of 2910 ADR reports
annually over a 5-year period (2012–2016). On average,
26% of reports came directly from HCPs. Reports also
came from pharmaceutical companies (67%), patients
(5%), others (2%) and clinical trials (1%). A breakdown
of reports is provided in Table S3 (see ESM). Reports
submitted by pharmaceutical companies would initially
have been notified to them by HCPs and members of the
public.
3.3 ADR Reporting Experience
Nurses had the least experience of ADR reporting, whereas
hospital pharmacists had the most (Fig. 1). There was no
statistically significant difference in the proportions of
hospital doctors, GPs, community and ‘other’ pharmacists
with no experience of ADR reporting (p = 0.247, Chi
square test for independence). Those with longer profes-
sional experience were more likely to have reported an
ADR on one or more occasions. There was a significantly
higher proportion of non-reporters in those who had
\ 10 years’ experience compared with those who had
[ 10 years’ experience (59.9% vs 35.8%, p\0.001, Chi
square test for independence).
3.4 Knowledge of ADR Reporting
Overall responses to the ADR knowledge items are pro-
vided in Table 2 and the sub-group analyses are presented
in Table S4 (see ESM). The average knowledge level
across all eight items was 5.66 correct items out of 8 (SD
1.60). Responses to some of the individual knowledge
items varied across HCPs (Table S4, see ESM) and this is
indicated by differences in mean knowledge score between
groups (p\0.001, one-way ANOVA) (Table 3).
Mean knowledge scores were also associated with pre-
vious experience of ADR reporting (p\0.001, one-way
ANOVA). Tukey post-hoc analysis (a = 0.05) found that
those who had reported an ADR more than three times in
the past had significantly higher knowledge scores (6.46,
SD 1.24) than those who had never reported an ADR (5.31,
SD 1.68), those who had reported an ADR once (5.47, SD
1.59) and those who had reported an ADR on two or three
occasions (5.85, SD 1.47). There was no association
J. O’Callaghan et al.
between ADR knowledge scores and duration of profes-
sional experience (p = 0.870, one-way ANOVA).
The majority of respondents agreed that they have
adequate knowledge to report ADRs, however some dif-
ferences between groups were observed (Fig. 2).
3.5 Familiarity with the Terms Biological Medicine
and Biosimilar Medicine
Survey respondents were asked how familiar they were
with the term (i) biological medicine and (ii) biosimilar
medicine. Differences in familiarity rates across groups
were observed (Table 4).
15%
35%
42%
43%
45%
76%
19%
29%
19%
15%
21%
7%
23%
18%
23%
16%
20%
12%
43%
18%
17%
26%
14%
6%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Hospital pharmacist+‡ (n=86)
General Praconer (n=197)
 'Other' pharmacist (n=53)
Hospital doctor (n=88)
Community pharmacist (n=169)
Nurse* (n=104)
No (0 mes) Yes (1 me) Yes (2 or more mes) Yes (> 3 mes)
Fig. 1 Differences in adverse drug reaction reporting experience
among healthcare professionals. Survey question: ‘‘Have you ever
reported an adverse reaction?’’ Reporting rates compared using Chi
square test for independence. A Bonferroni correction was applied.
Asterisk: the proportion of non-reporters in the nurse group was
higher than non-reporting proportions in each of the other groups
(p\0.001 in all cases). Plus sign: the proportion of non-reporters in
the hospital pharmacist group was lower than non-reporting propor-
tions in each of the other groups (pB 0.001 in all cases). Double
dagger: a higher proportion of hospital pharmacists had reported an
ADR on more than three occasions when compared with general
practitioners (p\0.001), nurses (p\0.001), community pharmacists
(p\0.001) and ‘other’ pharmacists (p = 0.003)
Table 1 Healthcare professional demographics
Profession Hospital
doctora
General
practitioner
Nurseb Community
pharmacist
Hospital
pharmacist
‘Other’
pharmacistc
Total
Group size (n) 88 197 104 169 87 53 698
Biological medicines used in practice, % (n)
Yes 78.4 (69) 74.2 (144) 52.9 (54) 88.7 (149) 83.9 (73) 29.4 (15) 73.0 (504)
No 18.2 (16) 19.1 (37) 21.6 (22) 9.5 (16) 13.8 (12) 49.0 (25) 18.6 (128)
Don’t know 3.4 (3) 6.7 (13) 25.5 (26) 1.8 (3) 2.3 (2) 21.6 (11) 8.4 (58)
Years in practice, % (n)
\ 5 10.2 (9) 17.3 (34) 3.8 (4) 13.6 (23) 4.6 (4) 20.8 (11) 12.2 (85)
5–9 13.6 (12) 15.7 (31) 1.9 (2) 21.3 (36) 21.8 (19) 22.6 (12) 16.0 (112)
10–19 31.8 (28) 23.4 (46) 20.2 (21) 31.4 (53) 40.2 (35) 26.4 (14) 28.2 (197)
20–29 21.6 (19) 22.8 (45) 39.4 (41) 18.9 (32) 24.1 (21) 20.8 (11) 24.2 (169)
[ 30 22.7 (20) 20.8 (41) 34.6 (36) 14.8 (25) 9.2 (8) 9.4 (5) 19.3 (135)
ESM electronic supplementary material
aHospital doctors practised in a wide variety of specialities—see Table S1 in the ESM
bNurses came from a wide variety of specialities—see Table S2 in the ESM
c‘Other pharmacists’ were not considered to be practising healthcare professionals. This group worked in industry (n = 22), academia (n = 12),
administration (n = 1), defence forces (n = 1), Health Service Executive (n = 5), medicines information (n = 2), primary care (n = 1),
regulatory (n = 7), representative organisation (n = 1) and retired (n = 1)
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Table 2 Adverse drug reaction reporting: responses to individual knowledge items
Questiona n %
correct
%
incorrect
% don’t
know
All serious ADRs are known before a medicine is marketed (no) 696 86.4 8.0 5.6
HCPs should report serious ADRs even if uncertain that the medicine caused the event (yes) 698 89.0 2.4 8.6
You have adequate knowledge on how to report ADRs (yes) 697 60.0 30.8 9.2
One case reported by an HCP does not contribute much to knowledge on medicine risks (no) 696 82.5 8.0 9.5
HCPs should report serious ADRs even if they do not have all the details of the event (e.g. complete
patient history, demographic data) (yes)
696 78.2 10.3 11.5
HCPs should report ADRs associated with overdose, misuse or error (yes) 695 60.7 15.0 24.3
Patients can report ADRs independent of a HCP (yes) 697 63.0 6.0 31.0
HPRA will not disclose an ADR reporter’s identity in response to a request from the public (yes) 696 45.7 7.5 46.8
ADR adverse drug reaction, HCP healthcare professional, HPRA Health Products Regulatory Authority
aCorrect answer is shown in brackets
Table 3 Mean knowledge
scores relating to adverse drug
reaction reporting and the
pharmacovigilance of biological
medicines among healthcare
professional groups
Profession n Mean knowledge scorea out of 8 Standard deviation
Adverse drug reaction reporting
Hospital doctor 88 5.45 1.58
General practitionerb 193 5.12 1.57
Nurse 100 5.49 1.54
Community pharmacist 166 5.69 1.53
Hospital pharmacistc 87 6.30 1.37
‘Other’ pharmacistd 52 7.17 1.13
Total 686 5.66 1.60
Pharmacovigilance of biological medicines
Hospital doctor 85 6.25 1.41
General practitionere 192 5.50 1.84
Nursef 99 4.41 1.67
Community pharmacist 167 5.97 1.68
Hospital pharmacistg 85 6.94 1.15
‘Other’ pharmacisth 53 7.08 1.1
Total 681 5.85 1.78
Data is compared using 1-way ANOVA with post-hoc analysis using Tukey test (a = 0.05)
ADR adverse drug reaction
aKnowledge scores were calculated from responses to eight knowledge items on (i) ADR reporting and (ii)
pharmacovigilance of biological medicines. A correct answer was given a score of 1. An incorrect answer
or a ‘don’t know’ response was given a score of 0
bGeneral practitioners had lower mean knowledge scores relating to ADR reporting than community
pharmacists
cHospital pharmacists had higher mean knowledge scores relating to ADR reporting than hospital doctors,
general practitioners, nurses and community pharmacists
d‘Other’ pharmacists had higher mean knowledge scores relating to ADR reporting than all other healthcare
professional groups
eGeneral practitioners had lower mean knowledge scores relating to the pharmacovigilance of biologicals
than hospital doctors, hospital pharmacists and ‘other’ pharmacists
fNurses had lower mean knowledge scores relating to the pharmacovigilance of biologicals than other
healthcare professional groups
gHospital pharmacists had higher mean knowledge scores relating to the pharmacovigilance of biologicals
than community pharmacists and hospital doctors
h‘Other’ pharmacists had higher mean knowledge scores than community pharmacists and hospital doctors
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Interestingly, 16 respondents (2.3%) indicated that they
were familiar with the term biosimilar medicine but not
with the term biological medicine.
3.6 Knowledge of Pharmacovigilance
Considerations for Biological Medicines
Overall responses to knowledge items relating to the
pharmacovigilance of biologicals are presented in Table 5
and the sub-group analysis is presented in Table S5 (see
ESM). The average knowledge scores across all eight items
was 5.85 correct items out of 8 (SD 1.78). Responses to
some of the individual knowledge items (Table S5, see
ESM) varied across HCP groups and this is indicated by
differences in mean knowledge scores between groups
(p\0.001, one-way ANOVA) (Table 3).
In order to confirm questionnaire robustness, mean
knowledge scores of those familiar and those not familiar
with the term ‘biological medicine’ were compared. Mean
knowledge scores were significantly higher among those
claiming to be familiar with the term ‘biological medicine’
(6.08, SD 1.70) compared with those who were not familiar
with the term (4.88, SD 1.78) (p\0.001, independent
t test).
3.7 Traceability of Biologicals
The majority of respondents (73%, n = 504) answered that
biological medicines were prescribed/dispensed or admin-
istered in their practice (Table 1). HCPs who used bio-
logicals were asked questions pertaining to their
traceability. The majority confirmed that they generally
recorded details of biological medicines by brand name
(Table S6, see ESM). Respondents were asked if, in their
practice, batch numbers of biological medicines that were
administered/dispensed to patients were generally recor-
ded. Practice behaviours were observed to differ between
professions (Fig. 3), although large proportions of hospital
doctors (39%) and nurses (24%) were unable to answer this
question. Respondents who indicated that their batch
number recording practices varied by medicine were asked
to give specific examples. A variety of responses were
given; examples included batch number recording for
specific monoclonal antibodies, vaccines, blood-derived
medicines, or medicines that were aseptically compounded
by the pharmacy.
ADR reports for biological medicines containing fil-
grastims, epoetins and infliximab were extracted from the
HPRA database and analysed for inclusion of brand name
and batch number details (Fig. 4). High levels of brand
name reporting were observed with lower levels of batch
number reporting, which varied across product types. As
some reports arose from literature/clinical trial settings,
follow-up to identify brand name or batch number would
not have been feasible.
HCPs who used biological medicines in their practice
were asked to rate the value of brand name and batch
number recording on two different scales. The mean score
for batch number recording on a 7-point scale anchored by
‘worthless (1) to valuable (7)’ was 5.47 (SD 1.65), sug-
gesting that HCPs perceive batch number recording as
valuable. However, on a 7-point scale anchored by ‘easy
(1) to difficult (7)’, HCPs perceived batch number
recording (4.61, SD 2.04) to be more difficult than brand
name recording (3.60, SD 2.25) (Table S7, see ESM).
47% 49% 49% 
63% 
89% 89% 
41% 44% 41% 
24% 
7% 8% 
13% 
8% 11% 
12% 
5% 4% 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Hospital
doctor
(n=88)
General
praconer
(n=197)
Nurse
(n=103)
Community
pharmacist
(n=169)
Hospital
pharmacist*
(n=87)
Other
pharmacist*
(n=53)
Yes No Don't know
Fig. 2 Healthcare professional
self-perception of their own
knowledge of adverse drug
reaction (ADR) reporting.
Survey question: ‘‘You have
adequate knowledge on how to
report ADRs?’’ Reporting rates
compared using Chi square test.
A Bonferroni correction was
applied. *Higher proportions of
both hospital pharmacists and
other pharmacists agreed with
this statement than hospital
doctors, general practitioners,
nurses and community
pharmacists (pB 0.001)
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3.8 Additional Monitoring
The majority of HCPs were aware of the concept of
additional monitoring, however awareness rates differed
between some groups (Table 6). A total of 568 HCPs
claimed to know about additional monitoring, but among
this number there were differences in awareness of the
inverted black triangle across HCP groups. In particular,
pharmacists had higher awareness of the black triangle than
hospital doctors, GPs and nurses (Table 6).
Those who knew about additional monitoring were
asked if they were aware when this applied to medicines
used in their practice. Of this number, 39.7% (n = 225)
were frequently or always aware, 36.4% (n = 207) were
sometimes aware and 23.7% (n = 134) were never or
rarely aware.
Among HCPs who worked directly with patients
(n = 506), over half (57.9%, n = 293) indicated that they
never or rarely informed patients when their medicines
were subject to additional monitoring. The subgroup
analysis is provided in Table S8 (see ESM).
4 Discussion
There are no recent studies assessing knowledge of ADR
reporting among HCPs in Ireland. More generally, it is not
known whether HCPs in Europe are aware of ‘additional
monitoring’. Although issues associated with the pharma-
covigilance of biological medicines are well documented,
again it is not known to what degree HCPs are cognisant of
these issues. A cross-sectional survey of HCPs in Ireland
was conducted in order to address these knowledge gaps.
The majority of HCPs were aware that ADRs could be
reported directly to the Regulatory Authority in Ireland.
However, nurses were less aware than other groups, sup-
porting recent conclusions by de Angelis et al. [29] that
nurses are not fully aware of their role in ADR reporting.
Nurses are responsible for drug administration and record
keeping, and of all the HCP groups surveyed, nurses may
often have the most contact with patients, making them
more likely to be present when an ADR occurs or is
identified [30]. ADR reports from nurses have been shown
to be valuable and of acceptable quality [31, 32], thus
corroborating the important contribution nurses can make
to pharmacovigilance and highlighting the need to increase
awareness about ADR reporting among nurses. On the
other hand, hospital pharmacists had the most experience
of ADR reporting, echoing findings from a US study that
found that pharmacists in general were more likely to have
reported an ADR in the past than hospital doctors [5]. Our
results suggest that pharmacy practice setting is an
important determinant of ADR reporting experience.
Hospital pharmacists had significantly more experience
with ADR reporting than community pharmacists, and the
proportion of non-reporters among community pharmacists
was in fact similar to the proportion of non-reporters
among hospital doctors and GPs. The important contribu-
tion made by hospital pharmacists to ADR reporting is also
confirmed when ADR reports made directly to the HPRA
by HCPs are considered. Over a 5-year period, the number
Table 4 Familiarity with the terms ‘biological medicine’ and
‘biosimilar medicine’ among healthcare professional groups
Profession n Familiara Not familiarb
Familiarity with the term biological medicine
Hospital doctor 88 90.9 9.1
General practitionerc 197 80.2 19.8
Nursed 103 45.6 54.4
Community pharmacist 169 87.0 13.0
Hospital pharmacist 87 95.4 4.6
Other pharmacist 53 100 0
Total 697 81.4 18.5
Familiarity with the term biosimilar medicine
Hospital doctor 88 69.3 30.7
General practitionere 197 47.2 52.8
Nursef 104 26.9 73.1
Community pharmacist 169 79.9 20.1
Hospital pharmacistg 87 95.4 4.6
Other pharmacisth 53 98.1 1.9
Total 698 64.8 35.2
Awareness rates compared using Chi square test for independence.
A Bonferroni correction was applied
HCP healthcare professional
aHCPs responded that they were ‘very familiar – complete under-
standing’ or ‘familiar – basic understanding’
bHCPs responded that they had ‘heard of the term – can’t define it’ or
‘never heard of the term’
cGeneral practitioners were less familiar with the term ‘biological
medicine’ than hospital pharmacists and ‘other pharmacists’
(p = 0.002 and p\0.001, respectively)
dNurses were less familiar with the term ‘biological medicine’ than all
other HCP groups (p\0.001 in all cases)
eGeneral practitioners were less familiar with the term ‘biosimilar
medicine’ than hospital doctors and community pharmacists
(p = 0.001 and p\0.001, respectively)
fNurses were less familiar with the term ‘biosimilar medicine’ than all
other HCP groups (pB 0.001 in all cases)
gHospital pharmacists were more familiar with the term ‘biosimilar
medicine’ than hospital doctors, general practitioners and community
pharmacists (p\0.001, p\0.001 and p = 0.002, respectively)
h‘Other’ pharmacists were more familiar with the term ‘biosimilar
medicine’ than hospital doctors, general practitioners and community
pharmacists (p\0.001, p\0.001 and p = 0.003, respectively)
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of reports received by the HPRA directly from community
pharmacists, GPs, nurses, hospital doctors and hospital
pharmacists was approximately even (Table S3, see ESM).
This suggests that hospital pharmacists made a very sig-
nificant contribution to ADR reporting, as according to
2017 figures, the number of hospital pharmacists working
in Ireland (6511) was much lower than the numbers of
practising community pharmacists [3612 (see footnote 1)],
GPs (approx 2500) [33], hospital doctors (9160 in public
health service) and nurses (approx 36,000 in public health
service) [34].
Previous research suggests that knowledge of ADR
reporting among HCPs could be improved [19–21, 23, 35].
Knowledge was measured using eight items (Table 2) and
correct answers for four of the knowledge items were high
([ 78%). Importantly, most HCPs know that individual
ADR reports are capable of contributing to knowledge on
medicine risks. This is reassuring, considering that indi-
vidual ADR reports can lead to re-evaluation of benefit–
risk balances for medicines [36]. Interestingly, almost one
in three HCPs (31.0%) did not know that patients can
report ADRs independent of a HCP. Although research on
the impact of patient ADR reporting is limited [37], reports
from patients do offer a different perspective from HCP
reports, are more detailed [37–40] and contribute to safety
signals [41]. The ‘other’ pharmacist group had the highest
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Fig. 3 Batch number recording
of biological medicines. Survey
question: ‘‘In your practice are
the batch numbers of biological
medicines that have been
administered/dispensed to
patients generally recorded?’’
Table 5 Pharmacovigilance considerations for biological medicines: response to individual knowledge items
Questiona n %
correct
%
incorrect
% don’t
know
ADRs associated with a patient changing between different brands of biological medicines should be
reported (yes)
694 92.1 1.0 6.9
In an ADR report it is better to identify a biological medicine by its non-proprietary name (e.g. insulin
glargine) instead of its brand name (no)
695 59.9 27.3 12.8
Biosimilars are the same as generic medicines (no) 693 75.2 10.7 14.1
Rare ADRs resulting from changes to the manufacturing process of a biological medicine can always be
predicted (no)
696 82.9 1.3 15.8
Keeping a biological medicine outside its recommended storage conditions may introduce or alter
immunogenicity (yes)
694 80.1 1.0 18.9
Different batches of the same biological medicine are always identical (no) 695 71.4 7.9 20.7
It is more important to include batch numbers in ADR reports for non-biological medicines than it is for
biological medicines (no)
693 61.3 17.7 20.9
In general, biological medicines pose a greater risk of immunogenicity than non-biological (chemical)
medicines (yes)
693 61.9 7.6 30.4
ADR adverse drug reaction
aCorrect answer is shown in brackets
1 Personal communication with the Pharmaceutical Society of
Ireland.
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mean knowledge scores on ADR reporting (Table 3),
reflecting the fact that many of this group worked in the
pharmaceutical industry (41.5%) and medicines regulation
(13.2%). Among practising HCPs, hospital pharmacists had
the highest mean knowledge scores, which is also reflected
in the fact that they have the most experience with ADR
reporting. Indeed, hospital pharmacists and ‘other’ phar-
macists were more confident in their own knowledge of
ADR reporting than other HCP groups (Fig. 2).
More hospital doctors, nurses and GPs were familiar
with the term ‘biological medicine’ than with the term
‘biosimilar medicine’ (Table 4). This could reflect the fact
that Ireland has low uptake of biosimilar medicines com-
pared with other European countries [13, 42, 43]. Famil-
iarity with the term biosimilar differed among HCP groups
(Table 4). For instance, fewer community pharmacists
(79.9%) were familiar with the term ‘biosimilar medicine’
than hospital pharmacists (95.4%), corroborating findings
from a 2015 survey carried out in France, where a higher
proportion of community pharmacists responded that they
were not at all informed about biosimilars compared with
hospital pharmacists [44]. A survey of HCPs conducted in
Ireland the year before this current study (2016) found
similar proportions of GPs and community pharmacists
claimed they were familiar with the term biosimilar.
However, there were higher familiarity rates among hos-
pital doctors in the earlier survey, which may be attributed
to the fact that this survey was conducted among doctors
who worked in specialities where biological medicines are
commonly used [13].
Knowledge of the pharmacovigilance of biological
medicines was measured using eight items (Table 5). A
sizeable proportion of HCPs (30.4%, n = 211) did not
know that biological medicines pose a greater risk of
immunogenicity than non-biological medicines. This is
concerning, considering that rare events related to
immunogenicity may rely heavily on ADR reports from
observant HCPs [12]. Almost one in five (18.9%, n = 131)
did not know that keeping a biological outside its recom-
mended storage conditions could introduce or alter
immunogenicity, suggesting that the importance of storage
and handling requirements for biologicals need to be better
communicated. Interestingly, statements relating to trace-
ability of biologicals had the lowest proportions of correct
answers. Knowledge gaps relating to the inclusion of brand
names and batch numbers in biological ADR reports were
identified. Knowledge of biological pharmacovigilance
was also observed to differ among HCP groups, with
hospital pharmacists and hospital doctors having higher
mean knowledge scores than GPs and nurses (Table 3).
The EMA advise that the brand name and batch numbers
of biologicals are recorded at all levels in the medicines
supply chain, including prescription, dispensing and patient
administration [9]. HCPs indicated that they generally
recorded biologicals by brand name (Table S6, see ESM),
reflecting the fact that electronic information recording
systems in Ireland generally default to brand name
recording. Traceability to batch level was lower and
recording practices differed between some professions
(Fig. 3). These recording practices are reflected in ADR
reports submitted directly to the HPRA. Analysis of reports
for certain biological medicines indicated high levels of
brand name inclusion in ADR reports with lower levels of
batch number reporting (Fig. 4). However, the levels of
batch number traceability in ADR reports were higher than
levels seen in other European spontaneous ADR databases
[17, 45, 46]. This may reflect efforts made by the HPRA to
(i) actively inform HCPs about ADR reporting require-
ments and (ii) follow-up with reporters for missing infor-
mation. Nevertheless, the results indicate that information
recording systems in Ireland may not fully support batch
traceability of biologicals. In Irish hospitals, clinical
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records are almost exclusively paper based, so manual
recording of batch number is necessary. In pharmacies,
there is no prompt for dispensing pharmacists to manually
record batch number details.
The person responsible for ADR reporting is likely to
vary according to the practice setting and ADR reporting
processes in place. Inclusion of the brand name and batch
number in an ADR report depends on availability of the
original packaging, whether exposure information is rou-
tinely recorded in medical, nursing or pharmacy records,
and whether the reporter has access to such records [18].
Willingness to report this information could also be an
influencing factor. HCPs were asked to rate brand and
batch number recording on scales anchored by worthless
(1) to valuable (7) and easy (1) to difficult (7). The results
show that HCPs perceive batch number recording as
valuable but also that recording batch numbers is difficult.
Steps aimed at improving batch number traceability [18] of
biologicals in Ireland and elsewhere are needed. Trace-
ability needs to be fully integrated into healthcare settings.
For instance, future information recording systems,
including the roll-out of seamless electronic patient health
records, could be designed to allow automatic recording of
brand and batch details upon dispensing and administra-
tion. Record linkage would also ensure that ADR reporters
have access to the necessary information.
The majority of respondents were aware of additional
monitoring (Table 6). However, awareness of the black
triangle symbol . that appears on the SmPC and the PL
was much higher among the three pharmacist groups than
among other HCPs. This suggests that the black triangle is
an effective way of communicating the additional moni-
toring status of a medicine to pharmacists. However,
improved communication on the meaning of the black
triangle is needed for hospital doctors, nurses and GPs.
Over half of HCPs (57.9%, n = 293) who worked directly
with patients and who knew about additional monitoring
never or rarely informed patients when their medicines
were subject to additional monitoring (Table S8, see ESM).
HCPs are considered an effective medium to inform
patients about additional monitoring [47] and are in a
position to encourage ADR reporting from patients
[40, 48]. Improving HCP awareness of the value of ADR
reporting by patients and encouragement of HCPs to
inform their patients about medicines subject to additional
monitoring may be a mechanism by which additional
safety information can be gathered.
This study revealed some differences in knowledge and
experience of ADR reporting among a diverse group of
HCPs. It is important that all HCPs involved in the care of
patients receiving medicines are appropriately informed
and empowered to contribute to the ongoing safety moni-
toring of medicines. Different strategies have been applied
in order to address underreporting and to improve knowl-
edge of and attitudes to pharmacovigilance [49, 50]. Sus-
tained education and training [51] will enable HCPs to
keep abreast of changes such as the introduction of addi-
tional monitoring of medicines. For example, specific
education [52] and practical training (e.g. ADR reporting
assignments) [31] for nurses is likely to encourage ADR
Table 6 Awareness of additional monitoring among healthcare
professionals
Profession n Percentage aware
Proportion aware of additional monitoringa
Hospital doctor 88 84.1
General practitionerb 197 67.0
Nursec 104 71.2
Community pharmacist 168 91.7
Hospital pharmacist 87 96.6
Other pharmacist 53 94.3
Total 697 81.5
Proportion aware of black triangled
Hospital doctor 74 35.1
General practitioner 132 35.6
Nursee 74 14.9
Community pharmacistf 154 86.4
Hospital pharmacistg 84 88.1
Other pharmacisth 50 94.0
Total 568 59.5
Awareness rates compared using Chi square test for independence.
A Bonferroni correction was applied
aSurvey question: ‘‘Prior to this survey were you aware that some
medicines are subject to additional monitoring’’ (Brief explanation of
additional monitoring provided)
bGeneral practitioners had lower awareness rates of additional mon-
itoring than community, hospital and ‘other’ pharmacist groups
(p\0.001 in all cases)
cNurses had lower awareness rates of additional monitoring than
community, hospital and ‘other’ pharmacist groups (p\0.001,
p\0.001 and p = 0.002, respectively)
dSurvey question: ‘‘Prior to this survey did you know that when a
medicine is subject to additional monitoring an inverted black triangle
symbol. appears beside the name of the medicine in the summary of
product characteristics and package leaflet?’’ (this question was only
asked to those who previously responded that they were aware of
additional monitoring)
eNurses had lower awareness rates of the black triangle than general
practitioners (p\0.001)
fCommunity pharmacists had higher awareness rates of the black
triangle than hospital doctors, general practitioners and nurses
(p\0.001 in all cases)
gHospital pharmacists had higher awareness rates of the black triangle
than hospital doctors, general practitioners and nurses (p\0.001 in
all cases)
h‘Other’ pharmacists had higher awareness rates of the black triangle
than hospital doctors, general practitioners and nurses (p\0.001 in
all cases)
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reporting from this cohort. Further to improving ADR
reporting, the increasing availability of biological medici-
nes, including biosimilars, make it necessary for HCPs to
implement appropriate practice behaviours in order to
ensure their traceability. As such, education on biological
medicines needs to be incorporated at undergraduate level
and beyond. The use of sustained awareness campaigns on
importance of ADR reporting including traceability issues
for biological medicines, along with further research into
appropriate educational interventions is warranted.
Low response rates were the main limitation of this
survey. However, in the case of GPs, the response rate was
not unexpected as we received similar response rates using
the same method of dissemination in a survey conducted the
year previously [13]. Response rates for nurses could not be
calculated owing to the method of survey distribution.
Although non-response biases must be considered in the
interpretation of the results, this is a large multidisciplinary
study from which the results may be generalisable to other
European countries where the same regulations and similar
HCP education standards apply. There were baseline dif-
ferences among the practising HCPs in terms of reported
experience with biologicals. The majority of hospital doc-
tors, GPs, community and hospital pharmacists responded
that they used biological medicines in their practice.
However, this proportion was lower for nurses as just over
half answered that biological medicines were used and one
in four indicated that they did not know. Respondent loca-
tion and educational institution may have impacted
responses received and this was not explored in the current
study. Questions pertaining to knowledge of the HPRA
(Q12, see ESM) and awareness of additional monitoring
(Q15 and Q16, see ESM) were phrased ‘‘Prior to this survey
did you know…’’. This may have introduced some bias as it
depended on the HCP reflection on their own prior knowl-
edge. Finally, an analysis of the HPRA ADR database was
conducted in order to determine traceability details in
reports for specific biological medicines, this may not be
representative of overall traceability of biologicals in ADR
reports received by the HPRA.
5 Conclusion
A substantial proportion of hospital doctors, GPs, nurses
and community pharmacists were found to lack confidence
in their own knowledge of ADR reporting, highlighting the
importance of ongoing HCP education and training in the
area of pharmacovigilance. Among practising HCPs, hos-
pital pharmacists had the most experience and highest
mean knowledge scores related to ADR reporting. This
highlights the important contribution hospital pharmacists
make to post-marketing surveillance. Although awareness
of additional monitoring is high, poor knowledge of the
inverted black triangle among hospital doctors, GPs and
nurses suggest that alternative methods to alert these
groups of the additional monitoring status of a medicine
may be warranted. One in three HCPs were unaware that
patients could report ADRs. Improved HCP awareness of
the contribution patients make to ADR reporting may help
generate additional safety data, especially for medicines
subject to additional monitoring. There appears to be a
knowledge gap relating to immunogenicity, storage and the
traceability of biological medicines for the purpose of ADR
reporting. HCPs in Ireland perceive that recording batch
numbers for biological medicines is valuable, but they also
perceive that the recording of batch numbers is more dif-
ficult than the recording of brand names. Further research
and measures to improve batch traceability of biologicals
in healthcare settings are needed.
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